Furthermore, since cancer patients with KRAS mutations do not benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, KRAS mutation testing can guide anti-EGFR therapy selection [3]. The gene discussed is KRAS; the disease is cancer.